Aclaris Therapeutics, Inc. is a clinical-stage specialty pharmaceutical company. The Company is focused on identifying, developing and commercializing differentiated drugs for the treatment of dermatological indications. The Company's lead drug candidate, A-101 Topical Solution, is a high-concentration hydrogen peroxide topical solution that the Company is developing as a prescription treatment for seborrheic keratosis (SK), a non-malignant skin tumor. Aclaris has completed over three Phase II clinical trials of A-101 in over 300 patients with SK. The Company has initiated a Phase II clinical trial of A-101 for the treatment of common warts. In addition to A-101, the Company is also developing A-102, a topical gel dosage form of hydrogen peroxide, for the treatment of both SK and common warts. It has in-licensed the rights to inhibitors of the Janus kinase (JAK) family of enzymes, for specified dermatological conditions.

Type
Public
HQ
Malvern, US
Founded
2012
Size (employees)
31 (est)
Aclaris Therapeutics was founded in 2012 and is headquartered in Malvern, US
Report incorrect company information

Aclaris Therapeutics Office Locations

Aclaris Therapeutics has an office in Malvern
Malvern, US (HQ)
400 101 Lindenwood Dr
Show all (1)
Report incorrect company information

Aclaris Therapeutics Financials and Metrics

Aclaris Therapeutics Financials

Aclaris Therapeutics's revenue was reported to be $1.68 m in FY, 2017
USD

Revenue (FY, 2017)

1.7 m

Gross profit (FY, 2017)

476 k

Gross profit margin (FY, 2017), %

28.3%

Net income (FY, 2017)

(68.5 m)

EBIT (FY, 2017)

(72.4 m)

Market capitalization (20-Apr-2018)

498.3 m

Cash (31-Dec-2017)

20.2 m
Aclaris Therapeutics's current market capitalization is $498.3 m.
Annual
USDFY, 2015FY, 2016FY, 2017

Revenue

1.7 m

Cost of goods sold

1.2 m

Gross profit

476 k

Gross profit Margin, %

28%
Quarterly
USDQ1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017

Revenue

684 k

Cost of goods sold

453 k

Gross profit

231 k

Gross profit Margin, %

34%
Annual
USDFY, 2015FY, 2016FY, 2017

Cash

9.9 m20.2 m

Accounts Receivable

481 k

Inventories

1.7 m

Current Assets

86.5 m200.2 m
Quarterly
USDQ1, 2016Q2, 2016Q3, 2016Q3, 2017

Cash

13.1 m31.8 m17.8 m

Current Assets

86.8 m95.6 m85.6 m

PP&E

417 k434 k461 k

Total Assets

87.3 m96.1 m86.1 m
Annual
USDFY, 2015FY, 2016FY, 2017

Net Income

(20.6 m)(48.1 m)(68.5 m)

Depreciation and Amortization

90 k120 k402 k

Accounts Payable

(359 k)1.8 m4.6 m

Cash From Operating Activities

(20.4 m)(34.6 m)(54.7 m)
Quarterly
USDQ1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017

Net Income

(13 m)(12.9 m)(10.7 m)(12.6 m)(27.4 m)(45.6 m)

Depreciation and Amortization

21 k50 k105 k

Accounts Payable

2 m3.3 m1.8 m831 k3.2 m3.1 m

Cash From Operating Activities

(6.9 m)(12.7 m)(22.7 m)(36.5 m)
USDY, 2017

Revenue/Employee

63.1 k

Financial Leverage

1.1 x
Show all financial metrics
Report incorrect company information

Aclaris Therapeutics News and Updates

Alopecia Market Key Players – Aclaris Therapeutics Inc, Berg LLC, Cassiopea SpA, Daewoong Pharmaceutical Co Ltd, Energenesis Biomedical Co Ltd, Histogen Inc and Hyundai Pharmaceutical Co Ltd Analysis and Forecast to 2022

WiseGuyReports.com with their unique quality of simplifying the market research study, presents a deep diving study report “Alopecia - Pipeline Review, H1 2018” Posted via Industry Today. Follow us on Twitter @IndustryToday
Report incorrect company information